Physician profile
Rohit Goyal
NPI 1881879724
$95,200.96
in general payments reported to CMS, 2019-2025
55 companies · $9,432 in 2025
The $9,432 reported for 2025 was more than what 95% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $689 · 2021: $5,535 · 2022: $5,747 · 2023: $55K · 2024: $18K · 2025: $9,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Food and Beverage: $11K · Travel and Lodging: $6,928 · Education: $4,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $59,500.76 |
| Food and Beverage | $10,960.13 |
| Travel and Lodging | $6,928.31 |
| Education | $4,986.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $63,478.74 | 2020-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Intuitive Surgical, INC. | $8,344.64 | 2021-2024 | |
| United Therapeutics Corporation | $6,789.86 | 2019-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals Lp | $2,037.89 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Ethicon INC. | $1,806.24 | 2021 | |
| Glaxosmithkline, LLC. | $1,629.63 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Noah Medical Corporation | $1,072.94 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,052.78 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Olympus Corporation of The Americas | $1,038.85 | 2023-2024 | Single Use Suction Valve (Sterile), Olympus, Vizishot 2 Flex |
| Ani Pharmaceuticals, INC. | $809.66 | 2022-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $783.00 | 2021-2025 | Glassia, Cuvitru |
| Insmed, INC. | $720.86 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $711.03 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $523.60 | 2020-2025 | Acthar |
| Amgen INC. | $425.85 | 2022-2025 | Tezspire |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.